Company research
Traws Pharma, Inc.
CIK 1130598Updated Sep 26, 2026
SecurityTRAW · NASDAQ · equity
Historical securities (2)
ONTX · OTC · equity · closed Jul 26, 2021ONTXW · NASDAQ · warrant · closed Jul 26, 2021Name history
Onconova Therapeutics, Inc. · through Apr 1, 2024ONCONOVA THERAPEUTICS INC · through May 26, 2009
TRAW price & chart
Loading TradingView…
NASDAQ:TRAW on TradingView ↗About the company
Pharma, Inc. Traws Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to meet real world challenges in the treatment of viral diseases. The Company is advancing novel investigational oral small molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health including seasonal influenza and H5N1 bird flu, negative-strand RNA viruses including Hantavirus, Ebola Virus Disease, Lassa Fever and COVID-19/Long COVID.
In the news
Traws Pharma Provides Regulatory Update on Influenza Program ↗
Recent filings
SCHEDULE 13G/A filing
10-Q filing
Results of Operations and Financial Condition · Regulation FD Disclosure
Items 2.02, 7.01, 9.01
SCHEDULE 13G/A filing
SCHEDULE 13G filing
Show 5 more recent filings
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 24,962,000Source | 22,683,000Source | 39,372,000Source | 55,478,000Source |
| Property, Plant and Equipment, NetUSD | 10,000Source | 22,000Source | 24,000Source | 38,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | — | 20,559,000Source | 38,522,000Source | — |
| Assets, CurrentUSD | 24,951,000Source | 22,660,000Source | 39,347,000Source | 55,430,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,848,000Source | 1,821,000Source | 561,000Source | 332,000Source |
| Other Assets, NoncurrentUSD | 1,000Source | 1,000Source | 1,000Source | 10,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 56,592,000Source | 12,011,000Source | 11,063,000Source | 9,358,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 36,000Source | 210,000Source | 209,000Source | 209,000Source |
| Retained Earnings (Accumulated Deficit)USD | -649,154,000Source | -482,631,000Source | -463,683,000Source | -444,719,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -42,000Source | -23,000Source | -33,000Source | -14,000Source |
| Additional Paid in Capital, Common StockUSD | 617,530,000Source | 493,116,000Source | 491,816,000Source | 490,644,000Source |
| Liabilities and EquityUSD | 24,962,000Source | 22,683,000Source | 39,372,000Source | 55,478,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 11,533,000Source | 9,220,000Source | 8,046,000Source | 6,115,000Source |
| Accounts Payable, CurrentUSD | 8,186,000Source | 5,619,000Source | 3,860,000Source | 2,757,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 3,121,000Source | 3,375,000Source | 3,960,000Source | 3,132,000Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -166,523,000Source | -18,948,000Source | -18,964,000Source | -16,163,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 12,000Source | 16,000Source | 14,000Source | 14,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,390,000Source | 1,301,000Source | 1,172,000Source | 576,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 646,000Source | 1,759,000Source | 1,103,000Source | -2,076,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -29,792,000Source | -17,932,000Source | -16,294,000Source | -19,487,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -3,648,000Source | -14,000Source | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | 14,000Source | — | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 33,976,000Source | — | — | 55,560,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 517,000Source | -17,936,000Source | -16,313,000Source | 36,045,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 21,338,000Source | 20,821,000Source | 38,757,000Source | 55,070,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -19,000Source | 10,000Source | -19,000Source | -28,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,390,000Source | 1,301,000Source | 1,155,000Source | 576,000Source |
| Amortization of Intangible AssetsUSD | 0Source | — | — | — |
| General and Administrative ExpenseUSD | 12,289,000Source | 9,094,000Source | 8,447,000Source | 9,425,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | 0Source | — | — | — |
| Investment Income, InterestUSD | 510,000Source | 1,391,000Source | 651,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -166,523,000Source | -18,948,000Source | -18,964,000Source | -16,163,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -54,674,000Source | — | — | — |
| Operating ExpensesUSD | 142,600,000Source | 20,524,000Source | 19,853,000Source | 16,722,000Source |
| Other Nonoperating Income (Expense)USD | 289,000Source | 1,350,000Source | 663,000Source | 12,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 55,041,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 24,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total RevenueUSD | 226,000Source | 226,000Source | 226,000Source | 226,000Source |
| Operating Income (Loss)USD | -142,374,000Source | -20,298,000Source | -19,627,000Source | -16,496,000Source |
| Other Nonoperating Income (Expense)USD | 289,000Source | 1,350,000Source | 663,000Source | 12,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -166,526,000Source | -18,948,000Source | -18,964,000Source | -16,163,000Source |
| Net Income (Loss) Attributable to ParentUSD | -166,523,000Source | -18,948,000Source | -18,964,000Source | -16,163,000Source |
| Earnings Per Share, BasicUSD per share | -35.21Source | -0.9Source | -0.91Source | -0.96Source |
| Earnings Per Share, DilutedUSD per share | -35.21Source | -0.9Source | -0.91Source | -0.96Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,552,685Source | 20,988,863Source | 20,908,235Source | 16,832,198Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,552,685Source | 20,988,863Source | 20,908,235Source | 16,832,198Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 0Source | — | — | — |
| General and Administrative ExpenseUSD | 12,289,000Source | 9,094,000Source | 8,447,000Source | 9,425,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -161,830,000Source | -18,949,000Source | -18,977,000Source | -16,153,000Source |
| Investment Income, InterestUSD | 510,000Source | 1,391,000Source | 651,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -54,674,000Source | — | — | — |
| Operating ExpensesUSD | 142,600,000Source | 20,524,000Source | 19,853,000Source | 16,722,000Source |
| Research and Development ExpenseUSD | — | 11,430,000Source | 11,406,000Source | 7,297,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | -111,849,000Source | — | — | — |
Filing attachments
tm2623190d1_ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 tm2623190d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights Advancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge study ───────────────────────────────────────────────────────────────────────────────────────────── Completed the April 2026 private placement and received shareholder approval of…
Read attachment ↗tm2617872d1_ex99-1.htm · 8-K · 2026-06-12
EX-99.1 2 tm2617872d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Traws Pharma Provides Regulatory Update on Influenza Program NEWTOWN, PA - June 12, 2026 - (GLOBENEWSWIRE) Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by t…
Read attachment ↗tm2615712d1_ex99-1.htm · 8-K · 2026-05-27
EX-99.1 2 tm2615712d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low pill burden option to manage existing and future outbreaks Interactions planned with the US Centers for Disease Control and Preve…
Read attachment ↗tm2614707d1_ex99-1.htm · 8-K · 2026-05-15
EX-99.1 2 tm2614707d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results Private financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027 Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent Advancing clinical candidates for the treatment of hantavirus infections NEWTOWN, PA, May 15, …
Read attachment ↗tm2611843d2_ex99-1.htm · 8-K · 2026-04-15
EX-99.1 2 tm2611843d2_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights Tivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity, Ratutrelvir topline Phase 2a data show a differentiated profile versus PAXLOVID® in COVID patients, with good overall safety; final study analysis underway Private financing of up to $60M (with $10…
Read attachment ↗tm2611843d1_ex4-1.htm · 8-K · 2026-04-15
EX-4.1 2 tm2611843d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT,…
Read attachment ↗